Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:00
11/16/22
11/16
11:00
11/16/22
11:00
OPNT

Opiant Pharmaceuticals

$20.16 /

+0.015 (+0.07%)

, MOR

MorphoSys

$3.75 /

-0.135 (-3.47%)

, STOK

Stoke Therapeutics

$9.49 /

-0.44 (-4.43%)

, STSA

Satsuma Pharmaceuticals

/

+

, PDSB

PDS Biotechnology

$8.26 /

-0.44 (-5.06%)

, INVVY

Indivior

$21.10 /

+1.1 (+5.50%)

, RHHBY

Roche

$41.36 /

+0.09 (+0.22%)

These names in the…

ShowHide Related Items >><<
STSA Satsuma Pharmaceuticals
/

+

STOK Stoke Therapeutics
$9.49 /

-0.44 (-4.43%)

RHHBY Roche
$41.36 /

+0.09 (+0.22%)

PDSB PDS Biotechnology
$8.26 /

-0.44 (-5.06%)

OPNT Opiant Pharmaceuticals
$20.16 /

+0.015 (+0.07%)

MOR MorphoSys
$3.75 /

-0.135 (-3.47%)

INVVY Indivior
$21.10 /

+1.1 (+5.50%)

OPNT Opiant Pharmaceuticals
$20.16 /

+0.015 (+0.07%)

04/28/22 Northland
Northland sees 'major buying pportunity' as Opiant wraps OPNT003 clinical work
12/08/21 Oppenheimer
Opiant Pharmaceuticals initiated with an Outperform at Oppenheimer
MOR MorphoSys
$3.75 /

-0.135 (-3.47%)

11/15/22 Citi
MorphoSys downgraded to Sell from Neutral at Citi
11/15/22 Stifel
MorphoSys downgraded to Hold from Buy at Stifel
10/24/22 Deutsche Bank
MorphoSys price target lowered to EUR 18 from EUR 30 at Deutsche Bank
10/24/22 Deutsche Bank
MorphoSys downgraded to Sell from Hold at Deutsche Bank
STOK Stoke Therapeutics
$9.49 /

-0.44 (-4.43%)

11/15/22 Cantor Fitzgerald
Stoke Therapeutics price target lowered to $20 from $38 at Cantor Fitzgerald
11/15/22 Credit Suisse
Stoke Therapeutics price target lowered to $38 from $50 at Credit Suisse
10/24/22 SVB Securities
Stoke Therapeutics upgraded to Outperform from Market Perform at SVB Securities
05/26/22 Cantor Fitzgerald
Stoke Therapeutics price target lowered to $38 from $68 at Cantor Fitzgerald
STSA Satsuma Pharmaceuticals
/

+

11/16/22 JonesTrading
Satsuma Pharmaceuticals downgraded to Hold from Buy at JonesTrading
11/15/22 Mizuho
Satsuma Pharmaceuticals downgraded to Neutral from Buy at Mizuho
10/10/22 SVB Securities
Satsuma Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
09/21/22 H.C. Wainwright
Satsuma price target raised to $18 from $15 at H.C. Wainwright
PDSB PDS Biotechnology
$8.26 /

-0.44 (-5.06%)

11/14/22 Chardan
PDS Biotechnology price target raised to $16 from $15 at Chardan
11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
INVVY Indivior
$21.10 /

+1.1 (+5.50%)

10/24/22 Morgan Stanley
Indivior upgraded to Overweight from Equal Weight at Morgan Stanley
03/25/22 Morgan Stanley
Indivior initiated with an Equal Weight at Morgan Stanley
RHHBY Roche
$41.36 /

+0.09 (+0.22%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
STSA Satsuma Pharmaceuticals
/

+

STOK Stoke Therapeutics
$9.49 /

-0.44 (-4.43%)

RHHBY Roche
$41.36 /

+0.09 (+0.22%)

PDSB PDS Biotechnology
$8.26 /

-0.44 (-5.06%)

OPNT Opiant Pharmaceuticals
$20.16 /

+0.015 (+0.07%)

RHHBY Roche
$41.36 /

+0.09 (+0.22%)

STSA Satsuma Pharmaceuticals
/

+

RHHBY Roche
$41.36 /

+0.09 (+0.22%)

PDSB PDS Biotechnology
$8.26 /

-0.44 (-5.06%)

OPNT Opiant Pharmaceuticals
$20.16 /

+0.015 (+0.07%)

MOR MorphoSys
$3.75 /

-0.135 (-3.47%)

On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:14
11/15/22
11/15
11:14
11/15/22
11:14
MOR

MorphoSys

$3.85 /

-0.12 (-3.02%)

, OPNT

Opiant Pharmaceuticals

$20.20 /

+ (+0.00%)

, PDSB

PDS Biotechnology

$7.89 /

+0.82 (+11.60%)

, STSA

Satsuma Pharmaceuticals

/

+

, RHHBY

Roche

$41.27 /

-1.98 (-4.58%)

, INVVY

Indivior

$20.00 /

+1.06 (+5.60%)

, XNCR

Xencor

$30.26 /

+0.695 (+2.35%)

These names in the…

ShowHide Related Items >><<
XNCR Xencor
$30.26 /

+0.695 (+2.35%)

STSA Satsuma Pharmaceuticals
/

+

RHHBY Roche
$41.27 /

-1.98 (-4.58%)

PDSB PDS Biotechnology
$7.89 /

+0.82 (+11.60%)

OPNT Opiant Pharmaceuticals
$20.20 /

+ (+0.00%)

MOR MorphoSys
$3.85 /

-0.12 (-3.02%)

INVVY Indivior
$20.00 /

+1.06 (+5.60%)

MOR MorphoSys
$3.85 /

-0.12 (-3.02%)

11/15/22 Citi
MorphoSys downgraded to Sell from Neutral at Citi
11/15/22 Stifel
MorphoSys downgraded to Hold from Buy at Stifel
10/24/22 Deutsche Bank
MorphoSys price target lowered to EUR 18 from EUR 30 at Deutsche Bank
10/24/22 Deutsche Bank
MorphoSys downgraded to Sell from Hold at Deutsche Bank
OPNT Opiant Pharmaceuticals
$20.20 /

+ (+0.00%)

04/28/22 Northland
Northland sees 'major buying pportunity' as Opiant wraps OPNT003 clinical work
12/08/21 Oppenheimer
Opiant Pharmaceuticals initiated with an Outperform at Oppenheimer
PDSB PDS Biotechnology
$7.89 /

+0.82 (+11.60%)

11/14/22 Chardan
PDS Biotechnology price target raised to $16 from $15 at Chardan
11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
STSA Satsuma Pharmaceuticals
/

+

11/15/22 Mizuho
Satsuma Pharmaceuticals downgraded to Neutral from Buy at Mizuho
10/10/22 SVB Securities
Satsuma Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
09/21/22 H.C. Wainwright
Satsuma price target raised to $18 from $15 at H.C. Wainwright
08/31/22 Ladenburg
Ladenburg starts Satsuma with a Buy, thinks STS101 can quickly gain share
RHHBY Roche
$41.27 /

-1.98 (-4.58%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
INVVY Indivior
$20.00 /

+1.06 (+5.60%)

10/24/22 Morgan Stanley
Indivior upgraded to Overweight from Equal Weight at Morgan Stanley
03/25/22 Morgan Stanley
Indivior initiated with an Equal Weight at Morgan Stanley
XNCR Xencor
$30.26 /

+0.695 (+2.35%)

11/09/22 Canaccord
Xencor price target lowered to $48 from $50 at Canaccord
11/08/22 Raymond James
Xencor added to Analyst Current Favorites list at Raymond James
10/13/22 Raymond James
Xencor upgraded to Strong Buy from Outperform at Raymond James
10/13/22 Raymond James
Xencor upgraded to Strong Buy from Outperform at Raymond James
XNCR Xencor
$30.26 /

+0.695 (+2.35%)

STSA Satsuma Pharmaceuticals
/

+

RHHBY Roche
$41.27 /

-1.98 (-4.58%)

PDSB PDS Biotechnology
$7.89 /

+0.82 (+11.60%)

OPNT Opiant Pharmaceuticals
$20.20 /

+ (+0.00%)

RHHBY Roche
$41.27 /

-1.98 (-4.58%)

XNCR Xencor
$30.26 /

+0.695 (+2.35%)

STSA Satsuma Pharmaceuticals
/

+

RHHBY Roche
$41.27 /

-1.98 (-4.58%)

PDSB PDS Biotechnology
$7.89 /

+0.82 (+11.60%)

OPNT Opiant Pharmaceuticals
$20.20 /

+ (+0.00%)

MOR MorphoSys
$3.85 /

-0.12 (-3.02%)

Recommendations
PDS Biotechnology price target raised to $16 from $15 at Chardan » 16:30
11/14/22
11/14
16:30
11/14/22
16:30
PDSB

PDS Biotechnology

$7.07 /

+1.435 (+25.49%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on PDS Biotechnology to $16 from $15 and keeps a Buy rating on the shares post the Q3 results.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$7.07 /

+1.435 (+25.49%)

PDSB PDS Biotechnology
$7.07 /

+1.435 (+25.49%)

11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$7.07 /

+1.435 (+25.49%)

PDSB PDS Biotechnology
$7.07 /

+1.435 (+25.49%)

On The Fly
Fly Intel: Pre-market Movers » 09:14
11/14/22
11/14
09:14
11/14/22
09:14
OPNT

Opiant Pharmaceuticals

$9.45 /

+ (+0.00%)

, LLY

Eli Lilly

$351.44 /

-15.56 (-4.24%)

, BIIB

Biogen

$289.42 /

-1.01 (-0.35%)

, TSN

Tyson Foods

$67.41 /

+0.975 (+1.47%)

, TSEM

Tower Semiconductor

$41.04 /

+0.25 (+0.61%)

, MNDY

Monday.com

$95.27 /

+11.44 (+13.65%)

, PDSB

PDS Biotechnology

$5.63 /

+0.07 (+1.26%)

, MGIC

Magic Software

$15.68 /

+0.3 (+1.95%)

, PNT

Point Biopharma

$9.10 /

-0.02 (-0.22%)

, OTLY

Oatly Group

$2.45 /

+0.325 (+15.29%)

, GRCL

Gracell

$3.83 /

+0.15 (+4.08%)

, ROIV

Roivant Sciences

$5.15 /

-0.03 (-0.58%)

, PTN

Palatin

$4.60 /

+0.15 (+3.37%)

, INVVY

Indivior

$18.94 /

-0.53 (-2.72%)

, RHHBY

Roche

$43.25 /

+0.72 (+1.69%)

Check out this morning's…

ShowHide Related Items >><<
TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

TSEM Tower Semiconductor
$41.04 /

+0.25 (+0.61%)

ROIV Roivant Sciences
$5.15 /

-0.03 (-0.58%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

PTN Palatin
$4.60 /

+0.15 (+3.37%)

PNT Point Biopharma
$9.10 /

-0.02 (-0.22%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

OPNT Opiant Pharmaceuticals
$9.45 /

+ (+0.00%)

MNDY Monday.com
$95.27 /

+11.44 (+13.65%)

LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

INVVY Indivior
$18.94 /

-0.53 (-2.72%)

GRCL Gracell
$3.83 /

+0.15 (+4.08%)

BIIB Biogen
$289.42 /

-1.01 (-0.35%)

OPNT Opiant Pharmaceuticals
$9.45 /

+ (+0.00%)

04/28/22 Northland
Northland sees 'major buying pportunity' as Opiant wraps OPNT003 clinical work
12/08/21 Oppenheimer
Opiant Pharmaceuticals initiated with an Outperform at Oppenheimer
LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

11/02/22 Wells Fargo
Eli Lilly price target raised to $365 from $305 at Wells Fargo
11/02/22 Barclays
Eli Lilly price target raised to $395 from $355 at Barclays
11/01/22 Piper Sandler
AbCellera price target lowered to $21 from $22 at Piper Sandler
10/18/22 Piper Sandler
Akouos downgraded to Neutral from Overweight at Piper Sandler
BIIB Biogen
$289.42 /

-1.01 (-0.35%)

11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
11/14/22 Oppenheimer
Biogen price target raised to $315 from $300 at Oppenheimer
11/01/22 Mizuho
Biogen price target raised to $325 from $270 at Mizuho
10/26/22 Goldman Sachs
Biogen upgraded to Buy at Goldman Sachs on Alzheimer's opportunity
TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

11/09/22 BofA
Tyson Foods downgraded to Underperform from Neutral at BofA
10/27/22 Piper Sandler
Tyson Foods price target lowered to $68 from $79 at Piper Sandler
09/13/22 Argus
Tyson Foods cut to Hold at Argus on inflation and strong USD headwinds
09/13/22 Argus
Tyson Foods downgraded to Hold from Buy at Argus
TSEM Tower Semiconductor
$41.04 /

+0.25 (+0.61%)

02/15/22 Needham
Tower Semiconductor downgraded to Hold from Buy at Needham
02/15/22 Craig-Hallum
Tower Semiconductor downgraded to Hold from Buy at Craig-Hallum
02/15/22 Jefferies
Tower Semiconductor downgraded to Hold from Buy at Jefferies
02/15/22 Northland
Intel deal for Tower Semiconductor 'makes sense,' says Northland
MNDY Monday.com
$95.27 /

+11.44 (+13.65%)

10/21/22 Citi
Monday.com price target lowered to $135 from $156 at Citi
10/20/22 Piper Sandler
Monday.com price target lowered to $130 from $180 at Piper Sandler
10/13/22 KeyBanc
KeyBanc bullish on Monday.com, initiates with an Overweight
10/13/22 KeyBanc
Monday.com initiated with an Overweight at KeyBanc
PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
MGIC Magic Software
$15.68 /

+0.3 (+1.95%)

PNT Point Biopharma
$9.10 /

-0.02 (-0.22%)

10/10/22 Oppenheimer
Oppenheimer starts radiopharmaceutical 'leader' Point Biopharma at Outperform
10/10/22 Oppenheimer
Point Biopharma initiated with an Outperform at Oppenheimer
09/18/22 Piper Sandler
Point Biopharma price target lowered to $17 from $19 at Piper Sandler
09/15/22 Truist
Point Biopharma initiated with Buy, $22 target at Truist
OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

09/13/22 Credit Suisse
Oatly Group downgraded to Neutral from Outperform at Credit Suisse
08/03/22 RBC Capital
Oatly Group price target lowered to $9 from $14 at RBC Capital
08/03/22 Barclays
Oatly Group price target lowered to $5 from $6 at Barclays
08/03/22 Piper Sandler
Oatly Group price target lowered to $6 from $8 at Piper Sandler
GRCL Gracell
$3.83 /

+0.15 (+4.08%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
ROIV Roivant Sciences
$5.15 /

-0.03 (-0.58%)

10/27/22 JPMorgan
Roivant Sciences initiated with an Overweight at JPMorgan
08/16/22 Citi
Roivant Sciences price target raised to $10 from $9 at Citi
05/23/22 SVB Securities
Roivant Sciences initiated with an Outperform at SVB Leerink
04/29/22 Cantor Fitzgerald
Roivant Sciences initiated with an Overweight at Cantor Fitzgerald
PTN Palatin
$4.60 /

+0.15 (+3.37%)

09/08/22 H.C. Wainwright
Palatin price target adjusted to $70 following reverse split at H.C. Wainwright
12/28/21 H.C. Wainwright
H.C. Wainwright bullish on Palatin as DED program 'goes pivotal as expected'
11/24/21 H.C. Wainwright
Palatin price target raised to $5 from $2 at H.C. Wainwright
INVVY Indivior
$18.94 /

-0.53 (-2.72%)

10/24/22 Morgan Stanley
Indivior upgraded to Overweight from Equal Weight at Morgan Stanley
03/25/22 Morgan Stanley
Indivior initiated with an Equal Weight at Morgan Stanley
RHHBY Roche
$43.25 /

+0.72 (+1.69%)

11/14/22 Jefferies
Roche failure in Alzheimer's a 'clearing event,' says Jefferies
11/14/22 Jefferies
Prothena scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

TSEM Tower Semiconductor
$41.04 /

+0.25 (+0.61%)

ROIV Roivant Sciences
$5.15 /

-0.03 (-0.58%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

PTN Palatin
$4.60 /

+0.15 (+3.37%)

PNT Point Biopharma
$9.10 /

-0.02 (-0.22%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

OPNT Opiant Pharmaceuticals
$9.45 /

+ (+0.00%)

MNDY Monday.com
$95.27 /

+11.44 (+13.65%)

MGIC Magic Software
$15.68 /

+0.3 (+1.95%)

LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

GRCL Gracell
$3.83 /

+0.15 (+4.08%)

BIIB Biogen
$289.42 /

-1.01 (-0.35%)

  • 08
    Nov
  • 14
    Sep
TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

BIIB Biogen
$289.42 /

-1.01 (-0.35%)

TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

ROIV Roivant Sciences
$5.15 /

-0.03 (-0.58%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

PTN Palatin
$4.60 /

+0.15 (+3.37%)

PNT Point Biopharma
$9.10 /

-0.02 (-0.22%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

MNDY Monday.com
$95.27 /

+11.44 (+13.65%)

LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

GRCL Gracell
$3.83 /

+0.15 (+4.08%)

BIIB Biogen
$289.42 /

-1.01 (-0.35%)

TSN Tyson Foods
$67.41 /

+0.975 (+1.47%)

PTN Palatin
$4.60 /

+0.15 (+3.37%)

OTLY Oatly Group
$2.45 /

+0.325 (+15.29%)

MNDY Monday.com
$95.27 /

+11.44 (+13.65%)

LLY Eli Lilly
$351.44 /

-15.56 (-4.24%)

BIIB Biogen
$289.42 /

-1.01 (-0.35%)

Earnings
PDS Biotechnology reports Q3 EPS (26c), consensus (28c) » 07:39
11/14/22
11/14
07:39
11/14/22
07:39
PDSB

PDS Biotechnology

$5.63 /

+0.07 (+1.26%)

PDS Biotech's cash…

PDS Biotech's cash balance as of September 30, 2022 was approximately $71.6 M. "Q3 has been monumental for PDS Biotech, and we continue to make strides towards commercialization of our lead candidate, PDS0101," stated CEO Frank Bedu-Addo. "We've remained focused on progressing our four Phase 2 clinical programs, most recently, announcing data from our IMMUNOCERV trial in locally, advanced cervical cancer. 100% of patients had a clinical response with tumor shrinkage of over 60% at the midpoint evaluation, and 89% of patients had a complete response with no evidence of disease at day 170, when treated with a combination of PDS0101 and chemotherapy...And, with VERSATILE-002 in which PDS0101 is combined with KEYTRUDA, we are preparing for a registrational trial after our successful end-of-Phase 2 meeting with the FDA. To date, we have presented PDS0101 Phase 2 efficacy data in over 60 patients and safety data in over 100 patients." CFO Matthew Hill stated, "...This August, we increased our cash position by entering into a loan agreement with Horizon Technology Finance Corporation, where we received an initial tranche of $25M in term loans. This financing provides PDS Biotech with the financial resources and runway needed to prepare for a registrational trial for our lead candidate, PDS0101, and to advance our preclinical pipeline."

ShowHide Related Items >><<
PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

Hot Stocks
PDS Biotechnology announces updated clinical data from IMMUNOCERV trial » 07:28
11/14/22
11/14
07:28
11/14/22
07:28
PDSB

PDS Biotechnology

$5.63 /

+0.07 (+1.26%)

PDS Biotechnology…

PDS Biotechnology announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer. These data expand upon results detailed in the abstract submitted to SITC 2022 that was released to the public on November 7. The enhanced data was presented in the poster titled, "IMMUNOCERV, an Ongoing Phase II Trial Combining PDS0101, an HPV-Specific T Cell Immunotherapy, with Chemotherapy and Radiation for Treatment of Locally Advanced Cervical Cancers," which highlights key findings from The University of Texas MD Anderson Cancer Center-led IMMUNOCERV Phase 2 clinical trial. The study is investigating PDS0101 in combination with standard-of-care chemoradiotherapy. New data from the study presented at SITC 2022 include:9 of the 17 patients have now completed a day 170 post-treatment Positron Emission Tomography, Computed Tomography scan to assess the status of their cancer; 100% of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage greater than60% at mid-point evaluation by MRI; 89% of patients treated with the combination of PDS0101 and CRT demonstrated a complete response on day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of PDS0101 showed signs of residual disease; 1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT. In addition, a second poster titled "Immune Correlates Associated with Clinical Benefit in Patients with Checkpoint Refractory HPV-Associated Malignancies Treated with Triple Combination Immunotherapy," reported data from the Phase 2 triple combination trial. The study is investigating PDS0101 in combination with two investigational immune-modulating agents: M9241, a tumor-targeting IL-12, and bintrafusp alfa, a bifunctional checkpoint inhibitor. Highlights included: A more than two-fold increase in HPV16-specific T cells in the blood of 79% of the evaluated patients; Increases on day 15 in several monitored immune correlates, such as granzyme B and interferon-gamma, were associated with a clinical response; Immune responses were associated with increases in natural killer cells, soluble granzyme B, IFN-gamma, tumor necrosis factor-alpha; These immunogenicity findings highlight the potential role of the combination in altering immune suppressive forces.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

PDSB PDS Biotechnology
$5.63 /

+0.07 (+1.26%)

Hot Stocks
PDS Biotechnology announces presentation on preliminary PDS0101 data » 08:29
11/07/22
11/07
08:29
11/07/22
08:29
PDSB

PDS Biotechnology

$4.97 /

-0.185 (-3.59%)

PDS Biotechnology…

PDS Biotechnology announced upcoming poster presentations of clinical data from two Phase 2 clinical trials of PDS0101 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer, SITC 2022, being held November 8-12, 2022 in Boston. The first abstract accepted for presentation, titled, "IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers," highlights data from IMMUNOCERV Phase 2 clinical trial. The study is investigating PDS0101 in combination with standard-of-care chemoradiotherapy for the potential treatment of cervical cancer in patients with large tumors over 5cm in size and/or cancer that has spread to the lymph nodes. Highlights from the study being presented at SITC 2022 include: 17 patients have been enrolled in the trial; 8 of the 17 patients had completed a Day 170 post-treatment Positron Emission Tomography, Computed Tomography scan to assess the status of the cancer; 87.5% of patients treated with the combination of PDS0101 and CRT demonstrated a complete response on Day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of PDS0101 showed signs of residual disease; In comparison, 74.1% of locally advanced patients who received CRT alone and were monitored at The University of Texas MD Anderson Cancer Center on a prospective protocol independent of IMMUNOCERV had a CR on PET CT at Day 170; The 1-year overall survival is 100% in patients treated with the combination of PDS0101 and CRT; The observed 1-year disease-free survival rate for IMMUNOCERV patients is 87.5%; Patients treated with the combination of PDS0101 and CRT had a 71% increase in multi-cytokine-inducing killer T cells within the tumors from baseline to end of treatment. This increase in activated T cells was not seen in patients receiving standard-of-care CRT. Toxicity of PDS0101 was limited to low-grade local injection site reactions. The second abstract, titled "Immune Correlates Associated with Clinical Benefit in Patients with Checkpoint Refractory HPV-Associated Malignancies Treated with Triple Combination Immunotherapy," reports data from the Phase 2 triple combination trial. The study is investigating PDS0101 in combination with two investigational immune-modulating agents: M9241, a tumor-targeting IL-12, and bintrafusp alfa, a bifunctional checkpoint inhibitor.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$4.97 /

-0.185 (-3.59%)

PDSB PDS Biotechnology
$4.97 /

-0.185 (-3.59%)

11/01/22 B. Riley
PDS Biotechnology initiated with Buy, $10 target at B. Riley
11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$4.97 /

-0.185 (-3.59%)

PDSB PDS Biotechnology
$4.97 /

-0.185 (-3.59%)

Over a month ago
Initiation
PDS Biotechnology initiated with Buy, $10 target at B. Riley » 07:45
11/01/22
11/01
07:45
11/01/22
07:45
PDSB

PDS Biotechnology

$5.26 /

-0.13 (-2.41%)

B. Riley analyst Kalpit…

B. Riley analyst Kalpit Patel initiated coverage of PDS Biotechnology with a Buy rating and $10 price target. The company's lead asset, PDS0101, is a lipid nanoparticle-based cancer vaccine that utilizes HPV16 antigens to trigger an immune response against HPV16-positive tumors, Patel tells investors in a research note. While the programs are in the early stages of development, PDS's initial data point toward PDS0101 producing a synergistic anti-tumor response in both doublet and triplet combinations, says the analyst.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

11/01/22 B. Riley
PDS Biotechnology initiated with a Buy at B. Riley
05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

Initiation
PDS Biotechnology initiated with a Buy at B. Riley » 04:52
11/01/22
11/01
04:52
11/01/22
04:52
PDSB

PDS Biotechnology

$5.26 /

-0.13 (-2.41%)

B. Riley initiated…

B. Riley initiated coverage of PDS Biotechnology with a Buy rating and $10 price target.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

PDSB PDS Biotechnology
$5.26 /

-0.13 (-2.41%)

Hot Stocks
PDS Biotechnology provides highlights from Head, Neck Cancer KOL rountable » 08:22
10/27/22
10/27
08:22
10/27/22
08:22
PDSB

PDS Biotechnology

$5.11 /

-0.33 (-6.07%)

PDS Biotechnology…

PDS Biotechnology provided highlights from its Head and Neck Cancer Key Opinion Leader, KOL, Roundtable. "We are very honored to have had the opportunity to conduct a KOL Roundtable featuring such an accomplished panel of experts in head and neck cancer research and treatment," said Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech. "As we advance the development of PDS0101 in multiple Phase 2 clinical trials targeting HPV-positive cancers, including recurrent and/or metastatic head and neck cancer, we are continually reminded of the need for improved treatment options for this devastating disease. On behalf of PDS Biotech, I would like to personally thank Drs. Gross, Price, and Weiss for discussing these important opportunities and where HPV-targeted immunotherapies, such as PDS0101, may help to improve the lives of head and neck cancer patients."

ShowHide Related Items >><<
PDSB PDS Biotechnology
$5.11 /

-0.33 (-6.07%)

PDSB PDS Biotechnology
$5.11 /

-0.33 (-6.07%)

05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
PDSB PDS Biotechnology
$5.11 /

-0.33 (-6.07%)

PDSB PDS Biotechnology
$5.11 /

-0.33 (-6.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.